对外合作项目登记表

序号:

 


一、       项目资料

11项目名称:1200万袋/年多层共挤膜输液袋、大容量注射剂

12项目类型: 新建[ √ ]  扩建[   ]  技改[   ]

允许[  ]  鼓励[   ]  限制[  ]

13项目描述(产品、技术、市场):

     此项目采用进口非PVC膜生产工艺,即制袋、灌装,封口在洁净区内同时完成,工艺环节少,可靠性高,质量可得到根本保证。具有袋轻,不易碎,无溶出物,不掉屑等特点,药液质量有保证。生产线可实现全部自动化生产,成本低,售价较高,市场前景广阔。

14合作方式

  ]合资   [    ]合作   [  ]技术引进   [   ]设备引进

[  ]独资      [  ]其它

1、  5拟合作期 

10 年

16投资总额 

180 万美元

17中方投资

总额   50 万美元  

其中:资金    设备10     技术10    建筑20万      土地10万    其它

18外方投资

总额   130 万美元  

其中:资金130    设备    技术    其它

19预计回收期 

3

110拟建项目选址:

 河南省清丰县城

111可提供的各种基础设施情况

供水设施齐全

供电设施齐全

 

交通

便利

通讯

设施良好

其他

 

112项目材料情况

[ ]详细资料

[ ]初步可行性研究

[ ]市场研究报告

[ ]技术调研

对外合作项目登记表

序号:

 


二、       公司资料

2.1企业概况

名  称

上海长征富民药业华中有限公司

地  址

河南省濮阳市清丰县

北环东路024

邮政编码

457300

成立日期

200210

注册资本

8600万元

公司总经理

谭自安

项目经理

岳臣轩

项目联系人

岳臣轩

电子信箱

cfnz@cfnz.com

电  话

03937237059

传  真

03937221368

所有制形式

私有

雇员人数

620

 

2.2发展概况

经营范围

主导产品有大输液、片剂、胶囊剂等大型剂80多个品种。

 

产品描述

主导产品有大输液500ml250ml200ml100ml,片剂有吲哒帕胺片;胶囊有替硝唑胶囊等40多个品种。

 

年销售收入

1亿元

税后利润

400万元

 

2.3技术情况

现有

技术情况

现已有两条GMP认证的大输液生产线、两个片剂、胶囊剂车间、年产大输液6000万瓶的生产能力,具有较强的技术力量。

 

 

 

 

 

 

 

 

                                                           NO.08

IDENTIFICATION FORM FOR PROPOSED PROJECT

(English Version)

Part One   Description of the Proposed Project

1·1 Project Title

   Annual 12 Million Multi-layered & Co-extruded Film Transfusion Sack and Bulk injecting Dosage.

1·2 Project Type

   ] New          [  ]Expansion        [  ]Rehabilitation 

[   ]Permitted        [  ] Encouraged       [  ]Restricted by the State

1·3 General Description of Project

   The project adopts production process of imported No-PVC-FILM. Sack-making, filling and sealing are finished in a clean room in one step, with less craftwork procedure and high reliable performance to guarantee quality. It has characteristics such as light weight, durability, no-spill, self-contained etc. The product assembly can be implemented totally automated production with low cost and good profit. It has a wide market foreground.

1·4 Intended Mode of Cooperation

[ ]Joint Venture      [ ]Cooperative           [  ]Technical Introduction      [    ]Equipment Import     [    ]Compensation Trade     [   ]Other forms

1·5 Intended Duration of Cooperation (in year)

   10

1·6 Total Investment  (in 1 million US Dollar)

   1.8

1·7 Local Investment and Structure (in 1 million US Dollar)

Total: 0.5

Break Down: Cash     Equipment 0.1     Technology 0.1      Buildings 0.2   Land 0.1    Others 

1·8 Foreign Part and Structure (in 1 million US Dollars)

Total: 1.3

Break Down: Cash 1.3    Equipment      Technology       Buildings    Land     Others

1·9 Pay back Period (in year)

   3

1·10 Project Site

    Qingfeng County,Henan Province

1·11 Description of Infrastructures & Facilities Available

Water

Available

Power

Available

Gas

 

Transportation

Convenient

Telecommunication

Convenient

                                                              No.

1·12Background Information

[ ] Detailed Project Description

[ ] Technical Study

[ ] Market Study

[ ] Pre·feasibility Study

Part Tow   Local Company Data

2·1 Summary of Chinese Partner

Company Name

Shanghai Changzheng Fumin Medicine Industry Co., Ltd

Address

No.024 Beihuan Road,Qingfeng County,Henan Province

Post Code

457300

Founding Date

2002.10

Registered Capital

86 million RMB

General Manager

Tan Zi-an

Project Manager

Yue Chenxuan

Contact Person

Yue Chenxuan

E-Mail

cfnz@cfnz.com

Phone

03937237059

Fax

03937221368

Ownership

Private

Number of Employees

620

 

2·2 Operation Conditions

Business Scope

Transfusion troche, capsules in four dosages and eighty varieties

Product Description

500ml, 250ml, 200ml, and 100ml I.V. liquid, Indapamide and Tinidazole tablets and capsules, in more than 40 varieties.

Annual Sales

100 million RMB

Profit after Tax

4 million RMB

 

2·3 Technology Conditions

Technology Available

Two GMP production assembly, two troche and capsule workshops, Annual production capability 60 million bottles. It has strong technology.